Wound Care Insurance Denied? Appealing HBO, NPWT, and Skin Substitute Denials

Chronic wounds — diabetic foot ulcers, pressure injuries, venous leg ulcers, and post-surgical wounds — affect millions of Americans and carry serious risks including infection, amputation, and death when inadequately treated. Advanced wound care interventions like hyperbaric oxygen therapy (HBOT), negative pressure wound therapy (NPWT), and cellular and/or tissue-based products (CTPs, also called skin substitutes) are proven tools in the wound care specialist's arsenal. Insurers deny all three at high rates. Understanding why — and how to fight back — can make the difference between healing and amputation.

Hyperbaric Oxygen Therapy (HBOT) Denials

Hyperbaric oxygen therapy involves breathing 100% oxygen at two to three times normal atmospheric pressure in a hyperbaric chamber. For wounds, it works by supersaturating tissue with oxygen, promoting angiogenesis, fighting anaerobic infections, and enhancing the body's healing response.

Medicare and most commercial payers cover HBOT for a defined list of indications. For wound care, the most commonly approved indications include:

• Diabetic lower extremity wounds with Wagner Grade III or higher
• Compromised skin grafts and flaps
• Soft tissue radionecrosis (radiation injury to soft tissue)
• Osteoradionecrosis
• Crush injuries
• Clostridial myonecrosis (gas gangrene)

Common denial reasons: "Wound does not meet Wagner Grade criteria." Medicare's HBOT coverage criteria for diabetic wounds require Wagner Grade III (deep ulcer with abscess, osteomyelitis, or joint sepsis) or higher. Wagner Grade II wounds (deep with exposed tendon or capsule) may not meet criteria unless additional factors are present. A wound care specialist's clinical staging — with measurement, photograph, and tissue characterization — is essential. If the wound is clinically significant but borderline in staging, document the wound bed status, surrounding tissue, and infection risk.

"Wound is not Wagner Grade — it is a pressure injury or venous ulcer." HBOT coverage for non-diabetic wounds is limited and varies by payer. Compromised skin grafts and flaps, however, are a covered indication when the graft is at risk of failure and HBOT has been ordered by a plastic or reconstructive surgeon.

"Inadequate prior wound care documentation." Most payers require documentation of 30 days of standard wound care without adequate healing before HBOT is approved. This "failed prior treatment" criterion requires detailed wound care records with measurements showing the wound has not decreased by 30–50% over 30 days.

Negative Pressure Wound Therapy (NPWT) Denials

NPWT (wound VAC therapy) uses sub-atmospheric pressure applied via a foam or gauze dressing to remove exudate, reduce edema, and promote granulation tissue formation. It is standard of care for many acute and chronic wounds.

Denials occur due to:

• Missing Prior Authorization Denied: How to Appeal" class="auto-link">prior authorization. NPWT requires prior authorization in most plans. If therapy was initiated in the hospital or urgent care setting and authorization was not obtained for home use, a retroactive authorization request with clinical justification is needed.
• "Wound is not appropriate for NPWT." Wounds with necrotic tissue, exposed blood vessels or nerves, or malignancy at the wound site may be contraindicated. If the wound care specialist has cleared the wound for NPWT, document this explicitly.
• Rental vs. purchase disputes. NPWT devices are typically rented rather than purchased. Coverage criteria for the rental period may apply.

Cellular and Tissue-Based Products (Skin Substitutes)

CTPs — including products like Apligraf, Dermagraft, Oasis, and Grafix — are advanced wound care products derived from human or animal tissue that support wound closure in complex chronic wounds. They are among the most frequently denied wound care interventions.

Denial reasons include:

• "Experimental or investigational." Most major CTPs have accumulated substantial clinical evidence and are included in wound care guidelines. Cite the Society for Vascular Surgery (SVS), the Wound Healing Society, and the American Podiatric Medical Association (APMA) guidelines for your specific wound type.
• "Not FDA-approved for this indication." Check the FDA clearance status of the specific product. Many CTPs are cleared as 510(k) devices for general wound care; others have specific diabetic foot ulcer indications.
• "Prior standard care not documented." CTPs require a trial of standard wound care (moist wound dressings, debridement, offloading for diabetic foot wounds) before authorization. Document the full wound care history with measurements.
• Frequency and quantity limits. Some payers limit CTP applications per episode of care. If additional applications are clinically indicated, document the wound's response to prior applications and the clinical rationale for continued treatment.

Building Your Wound Care Appeal

For all wound care modalities, your appeal should include:

1. Wound measurement history with serial photographs showing the wound's trajectory
2. Wound care specialist's clinical assessment including tissue characterization, infection status, and vascular assessment
3. Documentation of standard wound care that has been tried and failed
4. Clinical guidelines supporting the denied intervention for the specific wound type
5. Vascular surgery consultation if there is a vascular component — ruling out ischemia is required before many wound care approvals

Fight Back With ClaimBack

ClaimBack helps wound care patients build appeals that address the specific criteria insurers use to deny HBOT, NPWT, and skin substitutes. Our platform generates complete appeal letters with clinical documentation checklists.

Start your wound care appeal now

Related Reading

• What Is Medical Necessity?
• How to Write an Insurance Appeal Letter
• Internal vs. External Insurance Appeal: Which Should You File?